Introduction
============

The global incidence of spinal cord injury (SCI) is estimated from 23 per million inhabitants ([@b1-ijsc-12-331], [@b2-ijsc-12-331]). Patients with SCI suffer from permanent impairment, limitation of activity, low quality of life, loss of job and increased medical cost ([@b3-ijsc-12-331]). To overcome the permanent damage of SCI, many therapeutic approaches have been applied. Glial scar is known as the barrier to regenerated injured spinal cord, and it is formed from astrogliosis which is increased complex molecular and cellular responses, mainly morphological change and proliferation of astrocytes ([@b4-ijsc-12-331]). In astrogliosis, various pro-inflammatory cytokines and matrix metalloproteinases (MMPs) were involved. In the brain and spinal cord, MMPs are involved to both injury and repair cellular mechanisms ([@b5-ijsc-12-331]). In the spinal cord, MMP2 and MMP9 plays a pivotal role respectively to modulate astrocytes in the acute and chronic phases following SCI ([@b6-ijsc-12-331]). Astrocytes in the spinal cord are most abundant cells and mainly contribute in glial scar formation. Reactive astrogliosis is initiated with stimulated astrocytes migration at the site of injury and characterized by increased expression of glial fibrillary acidic protein (GFAP). Mesenchymal stem cells (MSCs) or precursor cell had been highlighted as one of them from inhibition of astrogliosis. However, role of MSC on acute astrogliosis is not defined clearly because treatment with MSCs has been delayed due to avoiding an acute hostile environment ([@b7-ijsc-12-331], [@b8-ijsc-12-331]). In addition, several reports support the protective role of acute astrogliosis in SCI ([@b9-ijsc-12-331]--[@b12-ijsc-12-331]). Anderson et al. ([@b9-ijsc-12-331]) reported astrocyte and acute gliosis improve regeneration of injured cord through decreasing scar formation and introducing axonal growth.

Inhibition of astrogliosis had been believed the key mechanism to recover from SCI by survived transplanted cells. These studies suggest that MSC treatment on acute astrogliosis improves during initial stage of recovery, and those evidences supprot to overcome adversities of animal study and promising recovery of SCI in clinical study. Therefore, in this study, we investigated how acute astrogliosis is associated with MSC transplantation in SCI rats.

Materials and Methods
=====================

Surgical procedures of spinal cord injury
-----------------------------------------

All animal experiments were approved and followed the regulations of the Institutional Animal Care and Use Committee (IACUC) of Kangwon National University (IACUC NO. KW-180518-2). For the comparison of behavioral and pathological outcome, female SD rats were anesthetized and exposed to severe SCI using the clipping compression technique ([@b13-ijsc-12-331], [@b14-ijsc-12-331]). After shaving and disinfected with povidone and 70% alcohol, midline incision was performed from T8 to T12 area. With serial dissection of fascia and muscle, T10 and T11 lamina were totally removed. The spinal cord injury was performed by compression of aneurysmal clips (occlusion pressure: 75 gm, Asculap, Oackville, ON, Canada). The clip was applied with full thickness of spinal cord, was left for 1 minute and then removed. For injection of NP-MSC or control, T10 and T12 vertebral bodies were fixed horizontally with forceps of fixation device.

Preparation and transplantation of MSC at acute SCI of rats
-----------------------------------------------------------

MSC were harvested from the tibia and fibula of two-week-old male Sprague--Dawley rat (Japan SLC, Inc. Hamamatsu, Japan). The MSC prepared on gelatin coated plate after removing RBCs as described previously ([@b15-ijsc-12-331]). At passage 5 of MSCs, MSCs were cultured in neuronal induction media composed of DMEM+10% FBS, 10 ug/L basic fibroblast growth factor (*β*-FGF, R&D Systems, Inc.), 10 ug/L human epidermal growth factor (hEGF, R&D Systems, Inc.), 1 mmol dibutyryl cyclicn AMP (dbcAMP, Sigma, St. Louis, MO) and 0.5 mmol isobutylmethylxanthine (IBMX, Sigma, St. Louis, MO) for 7 days following by Jiang's method ([@b16-ijsc-12-331]). For MSC trafficking, MSCs were tracked by CFDA tracker and then resuspended at a concentration of 10,000 cells/ul. MSC with CFDA tracker (20 ul, 200,000 cells/20 ul) were transplanted at 5 mm above epicenter of spinal cord after 1 hour from injury through the automatic stereotactic microinfusor (Model KDS-310; Muromachi Kikai Co., Tokyo, Japan) with 5 ul/min over 4 minutes. The needle was left in place for 5 minutes after injection.

Basso Beattie and Bresnahan (BBB) locomotor scale
-------------------------------------------------

Functional outcome was analyzed serially with the Basso Beattie and Bresnahan scale (BBB) at postoperative one day and weekly for four weeks. Two independent blinded examiners observed and assessed BBB for 4 min. For the comparison of behavioral outcome, twenty-five female SD rats were anesthetized and exposed to severe SCI using the clipping compression technique. MSC infused at 5 mm above injured spinal cord in each eight rats. Culture media or stem cell derivatives were infused at eight spinal cord injured rats for control. Nine rats were performed SCI only.

RNA isolation, real-time reverse transcription polymerase chain reaction (RT-PCR)
---------------------------------------------------------------------------------

According to the manufacturer's instructions, the RNeasy Mini Kit (Qiagen, Hilden, Germany) was used for extracting total mRNA from the cells and cDNA was synthesized using the ReverTra Ace qPCR RT Master Mix with gDNA remover kit (Toyobo, Osaka, Japan). Then, the quantification of the specific gene expression of Matrix metalloproteinase (MMP)-1, 2, 3, 7, 8, 9 was confirmed using a THUNDERBIRD SYBR qPCR Mix (Toyobo) under the 7500 Real-time PCR system (Applied Biosystems), and melting curve date was analyzed for identifying PCR specificity. The mRNA level was presented as 2^−ΔCt^, where Ct=threshold cycle for target amplification, ΔCt=Ct ~target\ gene~ (specific genes for each sample) --Ct ~internal\ reference~ (*GAPDH* for each sample). Design of primer sequences by Primer3 software (Whitehead Institute/MIT Center for Genome Research) was conducted with information of cDNA sequences obtained from GenBank for rat and [Table 1](#t1-ijsc-12-331){ref-type="table"} shows information and sequences of primers.

Enzyme linked immunosorbent assay (ELISA)
-----------------------------------------

Interleukin (IL)-1*α*, IL-10, C-X-C motif chemokine (CXCL)-2, CXCL-10, Tumor growth factor (TGF)-*β*, Tumor necrosis factor(TNF)-*α*, signal transducer and activator of transcription 3 (STAT3) and nuclear factor (NF)-*κ*B p65 were analyzed for evaluation of acute astrogliosis at 1, 3 and 7 d after SCI. Protein samples from rat spinal cord were prepared Protein samples from rat spinal cord were extracted and prepared with a protease inhibitor cocktail on ice. All ELISA kits (IL-1*α*, IL-10, CXCL-2, CXCL-10, TGF-*β*, TNF-*α*, STAT-3, NF-*κ*B pathway) were purchased from FineTest (Wuhan Fine Biological Technology Co., Ltd., Wuhan, Hubei, China) and used as per manufacturer's instructions. Microplates were read on an Epoch microplate reader (BioTek Instruments, Inc., Winooski, VT, USA). Cytokine levels were then extrapolated from a standard curve.

Western blot analysis
---------------------

Protein samples from spinal cord were prepared with RIPA lysis buffer with a protease inhibitor cocktail on ice, and equal amounts of isolated protein were separated on 10% SDS-polyacrylamide gels. The separated proteins were electroblotted onto 0.45-*μ*m nitrocellulose transfer membranes. The membranes were blocked with 5% skim milk in Tris-buffered saline supplemented with 0.1% Tween 20 (TBST) buffer for 1h and then probed with 1: 1000 diluted anti-NF-*κ*B p65 and anti-p-NF-*κ*B p65 (Ser536) primary antibodies for 24 h at 4°C. After 3 times washes for 10min each, polyclonal anti-rabbit HRP-conjugated secondary antibody were incubated for 1 h at room temperature and developed with a Pierce ECL Western Blot substrate. Band densitometry was calculated using Image J software analysis.

Immunofluorescence staining and confocal microscopy
---------------------------------------------------

Histopathologic analysis was undertaken at 7 and 28 d following injury. At 7 d after SCI, the extent of acute astrogliosis was checked by Glial fibrillary acidic protein (GFAP) staining at mid sagittal section of SCI. The cell population was checked with GFAP for glial cell, Neural/glial antigen (NG) 2 for oligodendroglial precursor cell (OPC), ionized calcium-binding adapter molecule (IBa) 1 for microglial cell at 7 d of SCI. At 4 weeks after SCI, histological outcome was determined by the relative mean percentage of spared white tissue by the Cavalieri method with Image J software analysis ([@b17-ijsc-12-331]). For it, the axial slides were selected every 100 um from epicenter to rostral and caudal direction with Hematoxylin & Eosin and Neurofilament staining. At 7 and 28 days after SCI, the survival and differentiation of MSC were checked with confocal microscope (Olympus FLUOVIEW - FV300).

Statistical analysis
--------------------

The statistical analysis was performed by SPSS. Paired t-test was used for comparison between MSC group and control. Results are shown as means±SD. Statistical analysis of significance was calculated by one-way ANOVA followed by Bonferroni post hoc test for multigroup comparisons (StatView 5.0; SAS institute, Cary, NC). The variation trends of BBB scores was analyzed using ANOVA followed by Turkey's post-hoc test and their score at 28 days were represented using box-and-whisker plots with statistical analysis of Bonferroni's multiple comparison test.

Results
=======

MSC graft enhanced functional and physiological improvement after SCI
---------------------------------------------------------------------

In order to evaluate the functional outcome of MSC grafted SCI rats, Basso Beattie and Bresnahan (BBB) locomotor scale was performed postoperatively. For 2 weeks, there was no difference of behavioral outcome between treated- and control group postoperatively. However, at 28 d after SCI, the BBB score of the MSC treated rats after SCI was significantly higher than SCI rats. In addition, culture media of MSCs treated rats was not significant different from SCI rats in BBB scale ([Fig. 1A and 1B](#f1-ijsc-12-331){ref-type="fig"}). We next analyzed the histological changes of the GFAP positive astrogliosis by measuring in mid sagittal section of SCI. At Day 7 after SCI, extensive astrogliosis and scar formation was observed at the injury site in MSC treated SCI rats compared with SCI or MSC-CM treated SCI rats ([Fig. 2B and 2C](#f2-ijsc-12-331){ref-type="fig"}). On the contrary of increased acute astrogliosis, MSC transplanted rats exhibited widely spared white matter at Day 28 postoperatively compared with SCI or MSC-CM transplanted SCI rats (p\<0.05) ([Fig. 2A](#f2-ijsc-12-331){ref-type="fig"}). Moreover, grafted MSCs were observed using CFDA-SE tracking under the confocal microscopy at both Day 7 and Day 28 after SCI compared to SCI alone ([Supplementary Fig. S1](#s1-ijsc-12-331){ref-type="supplementary-material"}).

MSC transplantation decreases release of proinflammatory cytokines and level of phosphorylation of NF-*κ*B p65 after SCI
------------------------------------------------------------------------------------------------------------------------

In order to determine whether MSCs after SCI modulate inflammatory response, protein or mRNA levels of pro/anti-inflammatory cytokines were analyzed by ELISA or RT-PCR. As shown in [Fig. 3](#f3-ijsc-12-331){ref-type="fig"} and [Supplementary Fig. S2](#s1-ijsc-12-331){ref-type="supplementary-material"}, protein levels of IL-1*α*, TNF-*α*, TGF-*β*, CXCL-2 or CXCL-10, were decreased in MSC transplanted SCI rats compared with SCI or MSC-CM transplanted SCI rats. We next determined the level of NF-*κ*B p65 to elucidate anti-inflammatory pathway of MSC transplanted SCI rats using western blot analysis. As shown in [Fig. 4A and 4B](#f4-ijsc-12-331){ref-type="fig"}, the phosphorylation level of the inflammatory transcriptional factor NF-*κ*B p65 at Ser536 of spinal cord was slightly decreased at 1-, 3- and 7 d after injury. The transcriptional level of NF-*κ*B p65 was confirmed in spinal cord tissue of rats by NF-*κ*B p65 ELISA ([Fig. 4C](#f4-ijsc-12-331){ref-type="fig"}).

Increased STAT3 and MMP2 levels in MSC treated rats after SCI
-------------------------------------------------------------

In astrogliosis, it is generally accepted that MMPs play a key role to mobilize astrocytes and inflammatory cells by disrupting blood brain barrier (BBB) ([@b5-ijsc-12-331]). Therefore, we next determined mRNA levels of MMPs in RT-PCR analysis. As shown in [Fig. 5](#f5-ijsc-12-331){ref-type="fig"}, MMP2 was significantly increased at 1 d in MSC transplanted rats after SCI, but not MSC-CM transplantation. We analyzed protein level of STAT3, which is a major microglial and neuro-inflammatory factor by western blot analysis. MSC grafted SCI rats exhibited increased level of STAT3 at day 1 whereas was not significantly different at 3- and 7 d compared with SCI or MSC-CM engrafted SCI rats ([Fig. 6](#f6-ijsc-12-331){ref-type="fig"}). Furthermore, levels of MMPs were analyzed to determine the endogenous levels of MSCs by RT-PCR analysis. As shown in Supple 2, MMP2 was significantly increased of MSCs suggesting that MSC exhibiting MMP2 is associated with its expression of MSC grafted SCI rats.

Discussion
==========

In acute phase of central nervous system (CNS) injury, reactive astrogliosis immediately develops following microglial activation after injury ([@b18-ijsc-12-331]). Sequentially, netruophil and T lymphocyte were infiltrated leading to recruiting large number of OPCs ([@b18-ijsc-12-331]--[@b20-ijsc-12-331]). In inflammatory responses at the site of injury, reactive astrocytes divide, migrate during the 2 to 7 day after injury, eventually fill the epicenter and make glial scar ([@b12-ijsc-12-331]). These changes of shape, number and location of astrocytes was defined as astrogliosis which resulted in glial scar in according to the severity of injury CNS ([@b4-ijsc-12-331], [@b20-ijsc-12-331], [@b21-ijsc-12-331]). Classically inhibition of astrogliosis had been believed the key mechanism of MSC to SCI. In contrary to classical belief, there were filed up evidences of protective role of acute astrogliosis. Faulkner et al. ([@b10-ijsc-12-331]), present astrocyte and acute gliosis improve regeneration of injured cord through decreasing scar formation. Wanner et al. ([@b12-ijsc-12-331]) focus on protective role of reactive astrocyte at 5 day which confine inflammatory and fibrodic cell from heathy tissue through STAT3 pathway. Okada et al. ([@b11-ijsc-12-331]) reported acute and subacute astrogliosis seclude the lesion area from healthy tissue by limiting disruption of the blood-spinal cord barrier, the amplification of an overwhelming inflammatory response and massive cellular degeneration.

Although it is widely recoginized MSC and MSC-based treatment are emering as a promising therapy in SCI, it is still controversial to make a decision an optimal timing of treatment. Regarding cellular survial, acute SCI provides a hostile environment on transplanted stem cells. Most studies have reported that the timing of treatment with MSCs was subacute phase of SCI ([@b7-ijsc-12-331], [@b22-ijsc-12-331], [@b23-ijsc-12-331]). In this study, we injected MSCs at early time point whether MSCs modulate astrogliosis at acute phase of SCI. It is known that gelatinase MMP2 and MMP9 are derived from astrocytes and microglia in astrogliosis ([@b24-ijsc-12-331]). MMP9 is a remarkable acute marker within 24 hours ([@b5-ijsc-12-331]), whereas MMP 2 is gradually increased during healing phase after SCI ([@b5-ijsc-12-331]). Sassoli et al. ([@b24-ijsc-12-331]) reported that MSC transplantation increased MMP2 and MMP9 expression of myoblast by paracrine effect resulting in substantially reducing muscle atrophy. Moreover, Lozito et al. ([@b25-ijsc-12-331]) reported that MSCs express MMP2 at cell surface and protein secretion. In agreement with previous observation, our findings exhibited that increased level of MMP2 from isolated MSCs of rats suggesting that upregulated MMP2 of transplanted MSCs increase level of MMP2 in injured spinal cord at day 1 after SCI ([Supplementary Fig. S3](#s1-ijsc-12-331){ref-type="supplementary-material"}).

We have seen that astrogliosis increased with MSC transplantation at 7 d after SCI. The area of lesion core and number of astrocyte were increased in MSC treatment group compared with SCI group. Moreover, infiltration of astrocytes and microglial cells were observed exhibiting increased astrogliosis. The rats of MSC group improved motor behavioral function with BBB score and white matter sparing in rats with SCI. Veeravalli et al. ([@b26-ijsc-12-331]) reported umbilical cord derived MSCs reduce the glial scar through the stimulation of MMP2 production. Renault-Mihara et al. ([@b27-ijsc-12-331]) reported that MMP2 was related to STAT pathway of astrogliosis in SCI. Okada et al. ([@b11-ijsc-12-331]) reported that reactive astrocytes play a pivotal role in repair of BBB and protecting neuron and oligodendroglial cells. Moreover, Anderson et al. ([@b9-ijsc-12-331]) reported that inhibition of STAT3 increased area of glial scar and disturbed recovery of SCI. Our findings have shown the increased protein levels of STAT3 and decreased NF-*κ*B p65 in SCI rats. In astrogliosis, protective pathway of STAT3 and detrimental pathway of NF-*κ*B has been discussed ([@b28-ijsc-12-331]). In STATs pathway, STAT3 plays a key role for modulating migratory function of reactive astrocytes to recover SCI ([@b11-ijsc-12-331], [@b19-ijsc-12-331]). In this study, MMP2 was significantly increased at 1 d and protein level of STAT3, not NF-*κ*B p65, exhibited similar tendency to MMP2. These results indicate that MSC-derived MMP2-STAT3 axis is associated transiently increased astrogliosis in SCI rats. In GFAP I*κ*Ba KO mice, the injury was dramatically improved at day 1 after SCI ([@b21-ijsc-12-331]). Brambilla et al. ([@b21-ijsc-12-331]) supports our findings to inhibit recovery of SCI through inhibition of NF-*κ*B p65 pathway.

In clinical trials, it is still remained to address MSC transplantation in SCI including quality of control in MSC as transplant, safety problem such as developing leukemia ([@b29-ijsc-12-331]). Moreover, establishment of optimized animal model of SCI should be considered the clinical situation ([@b30-ijsc-12-331], [@b31-ijsc-12-331]). Severity of SCI is one of critical factor to outcome of stem cell therapy. Parr et al. ([@b8-ijsc-12-331]) reported that neuronal stem cell produced significant functional improvement only for 27 g clip compression, not for 35 g. Clinical situation, the patients with incomplete SCI regained 75% of normal function without treatment. However, preclinical study usually used a model with less consistent moderate injury model. In addition, stem cell therapy should be advanced to acute CNS injury which is critical to clinical outcome ([@b32-ijsc-12-331], [@b33-ijsc-12-331]). As previous mention, stem cell was usually transplanted at day 7 after SCI in animal study which is beyond critical period of human SCI ([@b7-ijsc-12-331]). In addition, our previous studies have shown the method for more homogenous neuronal differentiated MSC and increased neuronal differentiation ([@b15-ijsc-12-331], [@b34-ijsc-12-331], [@b35-ijsc-12-331]). We transplanted MSC at acute severe SCI model to modulate astrogliosis. Acute transplanted MSC improved functional and histological outcome through increasing acute astrogliosis. For improving survival of MSC, further combined treatment needed to transplantation of acute SCI. Taken together, our findings suggest that early increased MMP2 derived from transplanted MSCs caused acute astrogliosis of injured spinal cord eventually leading to improve neurological and histrological outcine via MMP2-STAT3 axis. These data might contribute to unerstand the effect of acute treatment of MSC in SCI and its related diseases.

Supplementary Information
=========================

This work was supported by National Research Foundation (NRF) of the Korean government (2017R1D1A1A-02019187, NRF-2017R1A2B4006197).

**Potential Conflict of Interest**

The authors have no conflicting financial interest.

**Supplementary Materials**

Supplementary data including three figures can be found with this article online at <http://pdf.medrang.co.kr/paper/pdf/IJSC/IJSC-12-s18133.pdf>.

![Time course of behavioral recovery with acute treatment of MSC at severe SCI. For the comparison of behavioral outcome, twenty-five female SD rats were anesthetized and exposed to severe SCI using the clipping compression technique. MSC were infused at eight rats and MSC culture medium (CM) at eight rats for control. Nine rats were performed SCI. (A) Functional outcome was analyzed serially with the Basso Beattie and Bresnahan (BBB) scale at postoperative 1^st^ day and weekly for four weeks (28^th^ day). The statistical analysis was conducted by repeated measured analysis of variance followed by Turkey's post-hoc test. \*p\<0.05 and \*\*p\< 0.01 vs. score of D+1 at each groups. From 21 days after SCI, the rats with MSC treated group had better behavioral outcome with statistically significance than of SCI group. (B) The statistical analysis of box plots were accompanied by one-way analysis of variance followed by Bonferroni's multiple comparison test for comparing all pairs of columns to box-and-whisker plots of BBB score at 28^th^ day. Box plots display upper and lower quartiles and media values with each different color. This effects showed obvious differences between groups at 28 d (p\<0.05). \*p\<0.05 for MSC-CM-SCI or MSC-SCI vs. SCI. D; Day. Data are presented as the mean±SD.](ijsc-12-331f1){#f1-ijsc-12-331}

![Analysis of spared white mater and GFAP-positive astrogliosis with MSC treatment at acute or severe SCI. (A) At Day 28 after SCI, histological outcome was determined by represent 2 images of each groups (n=3) and their relative mean percentage of spared white tissue by the Cavalieri method. The axial slide was selected every 100 um from epicenter to rostral and caudal direction with Hematoxylin & eosin and neurofilament staining. The mean area of spared white mater in tissue was expressed as proportional area (percentage, %). MSC treated SCI rat had more spared white matter at the lesion epicenter compared with SCI or MSC-CM treated SCI rats. \*p\<0.05 compared with SCI group. (B) The astrogliosis was described using represent 2 images of each groups (n=3 for SCI or MSC-SCI rats and n=2 for MSC-CM-SCI rats). The extent of astrogliosis was measured by bright-filed microscopy with Glial fibrillary acidic protein (GFAP)-positive staining in mid sagittal section of SCI at 7 d after SCI at ×600 magnification. (C) The dotted line for area occupied by GFAP-(+) scar in (B) was shown as stereological quantification by image J. Data are presented as the mean±SD. The area of acute astrogliosis was increased by MSC treatment in SCI at 7 d compared with SCI or MSC-CM treatment in SCI. \*\*p\<0.01 compared with SCI at each group. ^\#\#\#^p\<0.001 compared with at 7 d in MSC-SCI group.](ijsc-12-331f2){#f2-ijsc-12-331}

![The effects of MSC transplantation on cytokines/chemokine related to astrogliosis in acute SCI. After SCI induction with or without MSC transplantation, the spine homogenates were isolated at day of first (D+1), third (D+3) and seventh (D+7) after SCI (n=3). The expression of cytokine/chemokine including (A) IL-1*α*, (B) TNF-*α*, (C) TGF-*β*, (D) IL-10, (E) CXCL2 and (F) CXCL10 was evaluated for acute astrogliosis using ELISA analysis. Each value was calculated along with regression analysis of corresponding standard curve. MSC treatment decreased the level of cytokine/chemokine in SCI rat. \*p\<0.05 for MSC-SCI compared with SCI at indicated time point.](ijsc-12-331f3){#f3-ijsc-12-331}

![The effects of MSCs transplantation on NF-*κ*B pathway in acute SCI. After SCI induction with MSC or MSC-CM transplantation, the spine homogenates were isolated at 1 to 7 d for western blot analysis and ELISA assay to detect neuron-inflammatory pathway through activation of NF-*κ*B p65 (p-NF-*κ*B, 65-kDa). (A) Western blot analysis determined the phosphorylation of NF-*κ*B p65 at Serine 536 residue. Total NF-*κ*B and *β*-actin were used for loading control. (B) The representative bands showed the ratio of p-NF-*κ*B p65 to total NF-*κ*B. (C) ELISA confirmed the activation of NF-*κ*B according to manufacturer's instruction. The value was calculated along with regression analysis of standard curve. MSC treatment decreased the activation of NF-*κ*B in SCI rat. Data are presented as the mean±SD. \*p\<0.05 for MSC-CM or MSC-SCI compared with SCI at indicated time point.](ijsc-12-331f4){#f4-ijsc-12-331}

![The effects of MSCs transplantation on matrix metalloproteinase (MMP) and STAT3 pathway in acute SCI. After SCI induction with MSC-CM or MSC transplantation, the spine homogenates were isolated at 1 to 7 d in the SCI after MSC transplantation for real-time qRT-PCR. The mRNA level of (A) *MMP1*, (B) *MMP2*, (C) *MMP3*, (D) *MMP7*, (E) *MMP8* and (F) *MMP9* was detected in indicated time point after SCI. The relative expression was calculated with 2^−ΔΔCT^ method and normalized with *GADPH*. Only *MMP2* was increased in MSC-treated SCI rat with statically significance at 1 d after SCI (D+1). Data are presented as the mean±SD of three animals for MSC-SCI or SCI, and two animals for MSC-CM-SCI. \*p\<0.05 and \*\*p\<0.01 compared with D+1 in each groups. ^\#^p\<0.05 for MSC-CM-SCI or MSC-SCI compared with SCI at indicated time point.](ijsc-12-331f5){#f5-ijsc-12-331}

![The effects of MSCs transplantation on STAT3 activation in acute SCI. After SCI induction with MSC-CM or MSC transplantation, the spine homogenates were isolated at 1 to 7 d in the SCI after MSC transplantation for ELISA analysis of activation of STAT3. The value was calculated along with regression analysis of standard curve. MSC treatment induces MMP2 expression and STAT3 activation in SCI rat. Data are presented as the mean±SD of three animals.](ijsc-12-331f6){#f6-ijsc-12-331}

###### 

Oligonucleotide primers and PCR cycling conditions

  Genes      GenBank number   Primer sequence          Size (bp)                  Temp (°C)   
  ---------- ---------------- ------------------------ -------------------------- ----------- ----
  *GAPDH*    NM_017008.4      ggacctcatggcctacatgg     cccctcctgttgttatgggg       179         60
  *MMP1*     NM_001134530     cttccccaaatcccatccagc    ttgagctcagcttctggcatg      160         60
  *MMP2*     BC074013         ggccgtacaatcttcactgca    agcacctttctttgggcacaa      182         60
  *MMP3*     NM_133523        tacggctgtgtgctcatccta    gcttccctgtcatcttcagcc      197         60
  *MMP7*     L24374           ttagttgggggactgcagaca    tcctcaccatccgtccagtac      169         60
  *MMP8*     NM_022221        tggaccttcagacaaccctgt    tcaactgttctcagctgggga      159         60
  *MMP9*     NM_031055        tcattcttcagtgccggaagc    ggacacatagtgggaggagct      183         60
  *Il1α*     NM_017019.1      gacaagcctgtgttgctgaa     Gaaagctgcggatgtgaagt       123         55
  *Tnfα*     NM_012675.3      tgcctcagcctcttctcatt     cccatttgggaacttctcct       108         55
  *Tgfβ*     NM_021578.2      tgagtggctgtcttttgacg     tgggactgatcccattgatt       146         55
  *Il10*     NM_012854.2      cccagaaatcaaggagcatttg   cagctgtatccagagggtcttca    100         55
  *Cxcl2*    NM_053647.1      agtgagctgcgctgtcaatg     gctctggatgttcttgaagtcaac   100         55
  *Cxcl10*   NM_139089.1      gggatccctctcgcaagaa      ctcagcgtctgttcatggaagt     100         55

Temp: Temperature.
